Hyperlipidemia, Familial CombinedHyperlipidemiasTriglyceridesHypolipidemic AgentsLipidsCholesterolTerminology as TopicHypertriglyceridemiaCholesterol, LDLHyperlipoproteinemia Type IVLipoproteinsApolipoproteins EHypercholesterolemiaLipid MetabolismApolipoproteins BCholesterol, HDLApolipoproteins CRisk FactorsApolipoprotein E2Apolipoprotein C-IIILipoprotein LipaseFenofibrateXanthomatosisLipoproteins, VLDLAnticholesteremic AgentsArteriosclerosisHydroxymethylglutaryl-CoA Reductase InhibitorsLiverObesityApolipoproteinsLipoproteins, LDLCholesterol, VLDLGynostemmaHyperlipoproteinemia Type IIReceptors, LDLDietary FatsAtherosclerosisHyperlipoproteinemia Type IIIDiabetes MellitusHypertensionPoloxamerBlood GlucoseHeptanoic AcidsDiet, AtherogenicApolipoprotein A-IInsulin ResistanceMice, Inbred C57BLCholesterol, DietaryDyslipidemiasPrevalenceDiabetes Mellitus, Type 2Metabolic Syndrome XCardiovascular DiseasesPostprandial PeriodFatty LiverBezafibrateEpichlorohydrinTime FactorsBody WeightTreatment OutcomeApolipoproteins AHyperlipoproteinemiasSimvastatinUnited StatesPhenotypeInsulinDisease Models, AnimalRetrospective StudiesPyrrolesNephrotic SyndromeHyperlipoproteinemia Type VHyperglycemiaMice, KnockoutApolipoprotein E3Fatty Acids, NonesterifiedGemfibrozilAge FactorsGadiformesApolipoprotein B-48Lipoproteins, IDLPravastatinChylomicronsPhytotherapyDiet, High-FatApolipoprotein A-IILipaseUpstream Stimulatory FactorsBiological MarkersCoronary DiseaseApolipoprotein B-100Risk AssessmentHyperlipoproteinemia Type IDietDiabetes ComplicationsProspective StudiesSeverity of Illness IndexCohort StudiesSex FactorsJapanPlant Extracts